Matthew  Strobeck net worth and biography

Matthew Strobeck Biography and Net Worth

Director of QuidelOrtho
Dr. Matthew W. Strobeck is Independent Director of the Company. Dr. Strobeck is currently the Managing Partner of Birchview Capital. Dr. Strobeck was a Partner and Member of the Management Committee and Advisory Board of Westfield Capital Management from 2008 until 2011, having served as a member of the investment team, specializing in healthcare and life sciences, from May 2003 to June 2008. Dr. Strobeck currently serves on the Boards of Accelerate Diagnostics, a medical diagnostics company; Tepha Inc., a medical device company; Biodesix, a private diagnostic company; and Monteris Medical, a medical device company. Dr. Strobeck received his B.S. from St. Lawrence University, a Ph.D. from the University of Cincinnati, a S.M. from the Harvard University/MIT Health Sciences Technology Program, and an S.M. from the MIT Sloan School of Management.

What is Matthew Strobeck's net worth?

The estimated net worth of Matthew Strobeck is at least $289,300.90 as of September 2nd, 2020. Dr. Strobeck owns 7,399 shares of QuidelOrtho stock worth more than $289,301 as of November 2nd. This net worth approximation does not reflect any other assets that Dr. Strobeck may own. Learn More about Matthew Strobeck's net worth.

How do I contact Matthew Strobeck?

The corporate mailing address for Dr. Strobeck and other QuidelOrtho executives is 9975 SUMMERS RIDGE ROAD, SAN DIEGO CA, 92121. QuidelOrtho can also be reached via phone at (800) 874-1517 and via email at [email protected]. Learn More on Matthew Strobeck's contact information.

Has Matthew Strobeck been buying or selling shares of QuidelOrtho?

Matthew Strobeck has not been actively trading shares of QuidelOrtho during the last ninety days. Most recently, on Wednesday, September 2nd, Matthew Strobeck bought 7,300 shares of QuidelOrtho stock. The stock was acquired at an average cost of $166.65 per share, with a total value of $1,216,545.00. Following the completion of the transaction, the director now directly owns 7,399 shares of the company's stock, valued at $1,233,043.35. Learn More on Matthew Strobeck's trading history.

Who are QuidelOrtho's active insiders?

QuidelOrtho's insider roster includes Michael Abney, Jr. (SVP), Douglas Bryant (CEO), Joseph Busky (CFO), William Ferenczy (SVP), Werner Kroll (SVP), Edward Michael (Director), Mary Polan (Director), Charles Slacik (Director), Randall Steward (CFO), and Matthew Strobeck (Director). Learn More on QuidelOrtho's active insiders.

Are insiders buying or selling shares of QuidelOrtho?

During the last year, QuidelOrtho insiders bought shares 1 times. They purchased a total of 2,150 shares worth more than $99,652.50. During the last year, insiders at the sold shares 24 times. They sold a total of 2,261,559 shares worth more than $82,700,460.24. The most recent insider tranaction occured on August, 7th when Major Shareholder Carlyle Group Inc. sold 78,180 shares worth more than $3,122,509.20. Insiders at QuidelOrtho own 1.0% of the company. Learn More about insider trades at QuidelOrtho.

Information on this page was last updated on 8/7/2024.

Matthew Strobeck Insider Trading History at QuidelOrtho

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/2/2020Buy7,300$166.65$1,216,545.007,399View SEC Filing Icon  
See Full Table

Matthew Strobeck Buying and Selling Activity at QuidelOrtho

This chart shows Matthew Strobeck's buying and selling at QuidelOrtho by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

QuidelOrtho Company Overview

QuidelOrtho logo
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $39.10
Low: $38.45
High: $39.66

50 Day Range

MA: $42.62
Low: $38.05
High: $46.35

2 Week Range

Now: $39.10
Low: $29.74
High: $75.86

Volume

418,992 shs

Average Volume

972,445 shs

Market Capitalization

$2.63 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.09